For ROS1-positive non-small cell lung cancer (NSCLC), crizotinib may be effective
the ONA take:
According to a new study published in the New England Journal of Medicine, crizotinib was effective against non-small cell lung cancer (NSCLC) with ROS1 gene rearrangement. In the phase 1, multi-center study, researchers at the University of Colorado Cancer Center in Aurora, Colorado, enrolled 50 patients with advanced NSCLC who tested positive for ROS1 gene rearrangement. Patients were treated with crizotinib orally. The researchers observed a response rate of 72%, which included 3 complete responses and 33 partial responses. Median progression-free survival was estimated at 19.2 months.
ROS1 gene rearrangements are found in only about 1% of patients with lung cancer. Patients with advanced stage NSCLC have a 5-year survival rate of about 2%. Researchers believe the results are promising and hope to confirm those results in future trials. They suggest that crizotinib may have a better effect on ROS1-positive NSCLC than it does against ALK-positive NSCLC.
Crizotinib, a tyrosine kinase inhibitor, was initially approved by the U.S. Food and Drug Administration (FDA) in 2011 for the treatment of patients with locally advanced or metastatic NSCLC) is that is anaplastic lymphoma kinase (ALK)-positive.
Crizotinib was effective against NSCLC with ROS1 gene rearrangement.
The New England Journal of Medicine reports positive results of a phase 1 clinical trial of the drug crizotinib against the subset of lung cancer marked by rearrangement of the gene ROS1.
In this multi-center study of 50 patients with advanced non-small cell lung cancer testing positive for ROS1 gene rearrangement, the response rate was 72 percent, with 3 complete responses and 33 partial responses. Median progression-free survival - the time it takes for the disease to resume its growth after being slowed by treatment - is estimated at 19.2 months with exactly half of patients remaining on observation for disease progression that has not yet occurred.
Sign Up for Free e-newsletters
- Is Radioimmunotherapy a Path Forward for Melanoma?
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS
- ASCO Endorses SIO Guideline for Integrative Therapies in Breast Cancer
- Seeking Reliable Information on Herbal Products
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Disparities Remain in Prevalence of Cancer Screening Tests
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
- Combined Digital Screening Best for Detecting Breast Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|